OTOF gene therapy (Otarmeni)
In April 2026 the US approved the first gene therapy for hearing loss, Otarmeni. In early, uncontrolled studies it improved hearing in most children deaf from faulty copies of one gene, OTOF — a rare cause of inherited deafness. It needs ear surgery, its approval is provisional, and it does nothing for ordinary age-related hearing loss.
This is a treatment only for confirmed OTOF deafness. For age-related hearing loss, don't wait for gene therapy: treat it with hearing aids now.
What it is
The OTOF gene makes otoferlin, a protein the synapse between the inner ear's hair cells and the hearing nerve needs to release its chemical signal. People with faulty versions of both copies of the OTOF gene are born with severe-to-profound deafness, even though the outer hair cells of the cochlea may still work.
Otarmeni (lunsotogene parvec-cwha), made by Regeneron, delivers a working copy of the gene into the cochlea using a modified, non-replicating adeno-associated virus (AAV) as a carrier. The gene is too large for one virus, so it is split across two.
Who it is approved for
On 23 April 2026 the US Food and Drug Administration (FDA) gave Otarmeni accelerated approval. It covers children and adults with severe-to-profound or profound hearing loss — worse than 90 dB on the audiogram scale at any frequency — from confirmed faulty versions of both copies of the OTOF gene, and only where the outer hair cells still work and the ear has not already received a cochlear implant.[1]
Accelerated approval is provisional: continued marketing depends on confirming that the effect lasts and that it helps speech development. The decision came 61 days after filing, under the FDA's national priority voucher pathway.[2]
The evidence: promising, but uncontrolled
The approval rests on a single trial with no comparison group. Of its first 12 children, published under the drug's development name DB-OTO, 9 reached the trial's hearing target (average thresholds of 70 dB or better) at 24 weeks.[3] By the time of the FDA's review, 24 children aged 10 months to 16 years had been treated, with hearing improved in 80% of the 20 who could be assessed.[4]
The longest follow-up comes from a separate Chinese product aimed at the same gene, AAV1-hOTOF, tested in a multicentre study with no control group. In 42 people aged 0.8–32.3 years, a single injection into the cochlea restored hearing in 90%. Hearing thresholds measured from the brainstem improved from worse than 97 dB to 42 dB at 2.5 years, and children did better than adults.[5]
Risks and limits
- Surgery. Treatment needs ear surgery plus a short course of whole-body steroids. The label lists procedure-related complications including vertigo, tinnitus, leakage of the fluid around the brain, facial-nerve paralysis, taste changes, meningitis, infection and inflammation of the inner ear.[6]
- Side effects in the Chinese study. No side effects severe enough to limit the dose occurred, but severe (grade 3) side effects included low neutrophil counts, a type of white blood cell.[7]
- Who has been studied. Every Otarmeni patient so far has been a child, and nobody 65 or older has been studied.[8]
How small the target is
OTOF accounts for only 2–8% of inherited deafness that comes without other symptoms, and genetic causes account for only about half of hearing loss present at birth.[9] Otarmeni matters mostly as proof that gene therapy can work in the ear.
Trials of gene therapy for GJB2, the commonest genetic cause of severe deafness from birth in many populations,[10] have been recruiting young children since May 2026; that gene fits in a single carrier virus.[11] A 20-adult safety study of donor cells meant to regrow the hearing nerve, injected during cochlear-implant surgery in people with age-related or nerve-related hearing loss severe enough for an implant, had not started recruiting as of August 2026, with results not expected before 2028.[12] Nothing here is available for typical age-related hearing loss.
What to do
- If you have age-related hearing loss, treat it now with hearing aids or, where aids no longer help, a cochlear-implant assessment. See Hearing.
- For a child with severe deafness from birth, the treatment applies only once genetic testing confirms faulty versions of both copies of the OTOF gene, only where tests show the outer hair cells still work, and only in an ear without a cochlear implant. The label also covers adults, though no adult has yet been treated with it.